1. The Defendant shall pay to the Plaintiff KRW 21,511,32 and the interest rate of KRW 20% per annum from April 10, 2014 to the day of complete payment.

1. Facts of recognition;

A. The Plaintiff is a company that manufactures and sells medicines, and the Defendant is a person who operates a B pharmacy in Namwon-si.

B. The Plaintiff and the Defendant began drug transactions from July 24, 2009. On September 13, 2010, the Plaintiff and the Defendant concluded the instant transaction agreement (hereinafter “A”) with the following terms and conditions (hereinafter “A”).

Article 1 A shall sell to B medicines, non-pharmaceutical drugs, and other products, etc. (hereinafter referred to as "products") produced by A according to the orders of B, at the price determined by A.

Article 3 Section B shall be paid in cash or by a bill or check even by a bank that can be paid within the date set by A from the date of receipt of the product, and in order to preserve the credit sales amount, A may present a plan to preserve claims, such as collateral and guarantor, to B.

Article 4 Section A may provide a sales incentive not exceeding 10% for the purchase amount during the period from the end of each year to the end of each year when the Party A purchased the products of Party A for at least a gold amount from the end of each year.

Article 5 If Article 5 Section A faithfully fulfills the settlement terms, such as the settlement form and the revolving date, presented by Party A at the time of credit sales, the amount to be recovered may be reduced by less than 1% within the legal permissible limit.

Article 6 In principle, A shall settle the amount corresponding to Articles 4 and 5 of this Arrangement and pay it by deducting it from the balance of credit sales and credit sales, but it shall be sealed in the prescribed form presented by A, and both parties shall make a normal tax return, and may make a lump sum deduction after accumulating it for a certain period due to the spread of office work.

C. The Plaintiff supplied drugs to the Defendant until the end of June, 2013, and thereafter, the supply of drugs was not made but only returned and received.

On the other hand, the Plaintiff is a transaction with the Defendant.